enGene (NASDAQ:ENGN) Shares Gap Up to $14.85

enGene Holdings Inc. (NASDAQ:ENGN)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $14.85, but opened at $15.49. enGene shares last traded at $15.00, with a volume of 3,243 shares changing hands.

Analysts Set New Price Targets

ENGN has been the topic of several research reports. Morgan Stanley began coverage on enGene in a research report on Friday, March 8th. They issued an “overweight” rating and a $40.00 price objective on the stock. Guggenheim began coverage on enGene in a research report on Monday, April 15th. They set a “buy” rating and a $34.00 target price on the stock. UBS Group began coverage on enGene in a research report on Thursday, March 28th. They set a “buy” rating and a $37.00 target price on the stock. SVB Leerink began coverage on enGene in a research report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 target price on the stock. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of enGene in a research report on Tuesday, February 20th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $34.40.

enGene Price Performance

The stock’s fifty day moving average price is $16.27.

Insider Activity at enGene

In related news, major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of the business’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $15.01, for a total value of $68,670.75. Following the completion of the sale, the insider now directly owns 3,084,107 shares of the company’s stock, valued at $46,292,446.07. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Hedge Funds Weigh In On enGene

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vivo Capital LLC acquired a new position in enGene in the fourth quarter valued at approximately $6,264,000. Omega Fund Management LLC acquired a new position in shares of enGene during the fourth quarter worth approximately $10,441,000. BVF Inc. IL acquired a new position in shares of enGene during the fourth quarter worth approximately $20,777,000. Finally, Fcpm Iii Services B.V. acquired a new position in shares of enGene during the fourth quarter worth approximately $80,097,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.